Amendments to the Claims:

1-29. (canceled)

30. (currently amended) A pharmaceutical formulation comprising risperidone form B with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the risperidone form B is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta .

31. (canceled)

32. (currently amended) The pharmaceutical formulation of claim 30, wherein the risperidone form B is further characterized by x-ray powder diffraction peaks at 10.8±0.2, 11.9±0.2, 12.6±0.2, 14.0±0.2, 17.5±0.2, 18.3±0.2, 19.9±0.2, 21.0±0.2, and 21.7±0.2 degrees two-theta.

33. (currently amended) ~~The~~ A pharmaceutical formulation comprising risperidone form B with a pharmaceutically acceptable carrier and/or pharmaceutically acceptable excipient ~~of claim 30~~, wherein the risperidone form B is characterized by a x-ray powder diffraction pattern substantially as depicted in Figure 2.

34. (previously presented) The pharmaceutical formulation of claim 30, 31, 32 or 33 wherein the pharmaceutical formulation is a dosage form suitable for oral administration or intravenous administration.

35. (previously presented) The pharmaceutical formulation of claim 34 wherein the dosage form is selected from the group consisting of tablet, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

36. (currently amended) A method for treating psychosis in a patient comprising ~~the step of~~ administering to the patient the pharmaceutical formulation of claim 30, ~~31,~~ 32 or 33.

37. (currently amended) The method of claim 36, wherein the risperidone form B in the pharmaceutical formulation is administered at a daily dosage of about 4 to about 16 mg per day.

38. (currently amended) The method of claim 36, wherein the risperidone form B in the pharmaceutical formulation is administered at a daily dosage of about 4 to about 8 mg per day.

39. (currently amended) A pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable ~~carrier~~ carriers and pharmaceutical acceptable ~~excipient~~ excipients, wherein the active ingredient consists essentially of risperidone form B.

40. (currently amended) The pharmaceutical dosage formulation of claim 39 wherein the dosage formulation is in a form selected from the group consisting of tablet, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

41. (currently amended) A method of treating psychosis in a patient comprising ~~the step of~~ administering to the patient the pharmaceutical dosage formulation of claim 39 or 40, wherein the risperidone form B in the pharmaceutical dosage formulation is administered at a daily dosage of about 4 to about 16 mg per day.

42. (new) A pharmaceutical formulation comprising risperidone form A with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable

excipient, wherein the risperidone form A is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.

43. (new) The pharmaceutical formulation of claim 42, wherein the risperidone form A is further characterized by x-ray powder diffraction peaks at 10.6±0.2, 11.4±0.2, 16.4±0.2, 18.9±0.2, 19.9±0.2, 22.5±0.2, 23.3±0.2, 25.4±0.2, 27.6±0.2 and 29.0±0.2 degrees two-theta.

44. (new) A pharmaceutical formulation comprising risperidone form A with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the risperidone form A is characterized by a x-ray powder diffraction pattern substantially as depicted in Figure 1.

45. (new) The pharmaceutical formulation of claim 42, 43 or 44, wherein the pharmaceutical formulation is a dosage form suitable for oral administration or intravenous administration.

46. (new) The pharmaceutical formulation of claim 45 wherein the dosage form is selected from the group consisting of tablet, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

47. (new) A method for treating psychosis in a patient, comprising administering to the patient the pharmaceutical formulation of claim 42, 43 or 44.

48. (new) The method of claim 47, wherein the risperidone form A in the pharmaceutical formulation is administered at a dose of about 4 to about 16 mg per day.

49. (new) The method of claim 48, wherein the risperidone form A in the pharmaceutical formulation is administered at a dose of about 4 to about 8 mg per day.

50. (new) A pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of risperidone form A characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.

51. (new) The pharmaceutical dosage formulation of claim 50, wherein the dosage formulation is in a form selected from the group consisting of tablet, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

52. (new) A method of treating psychosis in a patient, comprising administering to the patient the pharmaceutical dosage formulation of claim 50, wherein the risperidone form A in the pharmaceutical dosage formulation is administered at a dose of about 4 to about 16 mg per day.